Progress in Nanotechnology-Enabled Drug Delivery for Glioblastoma: Reports Since 2020
Nanomedicine Research Journal · 2025-06 · 10 (2) · 139-147
DOI: 10.22034/nmrj.2025.02.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nanomedicine Research Journal, 2025-06. Verfasst von Fatemeh Madani und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Glioblastoma (GBM) is the highest aggressive primary brain malignancy, with a median overall survival of only ~15 months despite maximal surgical resection followed by radiotherapy and chemotherapy. A major obstacle to effective treatment is the blood–brain barrier (BBB), which significantly prevents the intracranial delivery of most therapeutics. In this review, we first outline the advantages of using nanoparticle (NPs) in GBM treatment. We then critically examine recent advances in various types of NPs designed to traverse the BBB and enhance drug accumulation in GBM. Finally, we summarize ongoing clinical trials involving NP-enabled therapies and discuss emerging design principles and future research directions necessary to translate these platforms into clinical practice. By addressing the challenges of targeted delivery and controlled release, these innovative nanoplatforms hold promise to improve therapeutic efficacy and reduce systemic toxicity, ultimately aiming to extend survival and quality of life for GBM patients.
Schlagwörter
Zitieren
APA
Madani, F., Morovvati, H., Khosravani, M., & Adabi, M. (2025). Progress in Nanotechnology-Enabled Drug Delivery for Glioblastoma: Reports Since 2020. Nanomedicine Research Journal, 10(2), 139-147. https://doi.org/10.22034/nmrj.2025.02.004
Vancouver
Madani F, Morovvati H, Khosravani M, Adabi M. Progress in Nanotechnology-Enabled Drug Delivery for Glioblastoma: Reports Since 2020. Nanomedicine Research Journal. 2025;10(2):139-147. doi:10.22034/nmrj.2025.02.004
BibTeX
@article{Madani2025,
author = {Madani, Fatemeh and Morovvati, Hassan and Khosravani, Masood and Adabi, Mahdi},
title = {Progress in Nanotechnology-Enabled Drug Delivery for Glioblastoma: Reports Since 2020},
journal = {Nanomedicine Research Journal},
year = {2025},
volume = {10},
number = {2},
pages = {139--147},
doi = {10.22034/nmrj.2025.02.004}
}
EUVIMED